Novo Nordisk stock tumbled Friday — pulling Corbus Pharmaceuticals into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.Please watch the video at ...
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.